AstraZeneca stock gains 1.77% as strong oncology-driven revenue and earnings growth boosts sentiment

Traders Union
All News
Financial News
AstraZeneca rises 1.77% to GBX 15288

Highlights

AstraZeneca delivered 8% revenue and 11% earnings per share growth, led by strong oncology and rare disease performance.
Promising results from the EMERALD-3 trial in hepatocellular carcinoma are advancing regulatory discussions pending further endpoint data.
Shares remain in a bullish trend with high probability of stabilizing in the GBX 14,950–15,650 range, though multiple overbought signals warrant caution.

Oncology gains and asset manager outflows shape sentiment after results

AstraZeneca posted strong financial results, reporting 8% revenue growth and 11% earnings per share growth, with oncology and rare diseases driving performance. In addition, positive clinical data from the EMERALD-3 trial in hepatocellular carcinoma showed a promising trend toward improved overall survival with a new therapy, as discussions continue with regulators while awaiting final secondary endpoint results. Cidel Asset Management Inc. reduced its holdings in AstraZeneca by 6% during the fourth quarter.

Overbought signals emerge as bullish trend meets support at Kijun

AZN maintains a clear bullish structure, consistently above all major moving averages (MA-20, MA-50, MA-200), while the Ichimoku Kijun at GBX 14,510.00 acts as immediate support. Momentum is predominantly positive, with a neutral MACD on D1 but a strong buy on higher timeframes, and the ADX suggests trend strength weekly despite neutrality daily. Oscillators such as RSI (66.48), Stoch RSI, and CCI signal overbought conditions, and intraday indicators such as BBP and the Awesome Oscillator confirm strong upward momentum — though persistent overbought readings highlight some risk of a near-term pause or pullback.

High probability of upside as range expands with stable momentum

Over the next five trading days, AZN is expected to fluctuate within a volatility band between GBX 14,950.00 and GBX 15,650.00, aligning with typical range expansion given current price action. The probability of further upward movement remains very high (over 80%), suggesting price stabilization near session highs. A move above GBX 15,650.00 would indicate additional upside potential, while a decline below GBX 14,950.00 may lead to a short-term pullback toward key supports.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca maintaining technical strength above key moving averages, with positive financials and robust momentum. He remains cautious due to persistent overbought signals and the potential for a near-term pullback. The base case is for AZN to stabilize within the GBX 14,950.00–15,650.00 range, but a drop below support could trigger a correction. "Until the price breaks below GBX 14,950.00, my bias stays neutral with a defensive stance."

Earlier, analysts noted that AstraZeneca’s consistently bullish technical setup and encouraging clinical developments positioned the stock for ongoing strength. The latest combination of robust earnings growth and positive trial momentum further reinforces this outlook, with a break above GBX 15,650.00 likely to trigger the next phase of upside potential.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.